...Holding AG (SIX:SANN) fell CHF1.63 (27%) to CHF4.50 Tuesday after it discontinued development of Puldysa idebenone...
...also withdraw an MAA for Puldysa for the indication. The short-chain benzoquinone is marketed as Raxone...
...Staff VIR-7831 BNT162b2 Sovrima (Brand), Raxone (Brand), Catena (Brand), Puldysa (Brand) SNT-MC17 (Compound #), idebenone (Generic), Raxone (Other), Catena...

...support U.S. and China clinical trials, said Xiao. Santhera Pharmaceuticals Holding AG (SIX:SANN) markets Raxone idebenone...

...an option to license the program, which would complement its other pipeline product for DMD, idebenone...
...would complement Santhera's development of Raxone idebenone for preserving respiratory function in typically non-ambulant patients. Raxone...
...said the company submitted an application to EMA in May seeking conditional marketing authorization of idebenone...

...Santhera Pharmaceutical Holding AG (SIX:SANN) submitted an MAA to EMA seeking conditional approval of Puldysa idebenone...
...cdc 501, CC-5013) Sovrima (Brand), Raxone (Brand), Catena (Brand), SNT-MC17 (Compound #), idebenone (Generic), Raxone (Other), Catena...

...Chiesi gains rights to Santhera's Raxone for LHON Santhera Pharmaceuticals Holding AG (SIX:SANN) granted Chiesi Farmaceutici...
...Farmaceutici S.p.A. (Parma, Italy) exclusive, worldwide rights outside of the U.S. and Canada to Raxone idebenone...
...Zipkin, Staff Writer Sovrima (Brand), Raxone (Brand), Catena (Brand), SNT-MC17 (Compound #), idebenone (Generic), Raxone (Other), Catena...

...April 4, when it announced the financing. The placement agent was Mirabaud Securities. Santhera's Raxone idebenone...
...Lieu, Staff Writer Sovrima (Brand), Raxone (Brand), Catena (Brand), SNT-MC17 (Compound #), idebenone (Generic), Raxone (Other), Catena...

...idebenone Treat Duchenne muscular dystrophy (DMD) Submit conditional MAA 2Q19 Santhera Pharmaceuticals Holding AG (SIX:SANN) Raxone...
...Treat Duchenne muscular dystrophy (DMD) Submit conditional MAA 2Q19 Santhera Pharmaceuticals Holding AG (SIX:SANN) Raxone idebenone...

...Santhera said it will submit an application to EMA next quarter seeking conditional approval of idebenone...
...Duchenne muscular dystrophy who are not using glucocorticoids. EMA's CHMP has twice recommended against expanding idebenone's...
...Eaton, Staff Writer Sovrima (Brand), Raxone (Brand), Catena (Brand), SNT-MC17 (Compound #), idebenone (Generic), Raxone (Other), Catena...

...Santhera said long-term treatment with Raxone idebenone reduced the annual rate of decline in percent predicted...
...Scientific Conference in Orlando in April. In 2014, Santhera said Raxone met DELOS’s primary endpoint. Raxone...
...Wong, Staff Writer Sovrima (Brand), Raxone (Brand), Catena (Brand), SNT-MC17 (Compound #), idebenone (Generic), Raxone (Other), Catena...

...Dupixent dupilumab Atopic dermatitis in adolescents PDUFA date 3/11/19 Santhera Pharmaceuticals Holdings AG (SIX:SANN) Raxone idebenone...